ABSTRACT: BIOSPECIMEN AND PATHOLOGY CORE The purpose of the Biospecimen and Pathology Core is to provide biospecimens and pathology services to support the two planned Li-CAD P20 Projects and those research studies proposed in the context of the Developmental Research Program and to prepare for a P50 SPORE expansion of services. The Biospecimen Core provides expertise in the interpretation of tissue-based assays especially in the context of biomarker studies, ensures quality standards and the ethical use of biospecimens and provides Core services in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators. SA1. Provide biospecimens needed for Projects 1 and 2 from AI/AN patients with liver disease, cirrhosis and HCC, as well as from appropriate non-AI/AN comparison/control patients Our Li-CAD project will obtain plasma, serum, liver tissue and HCC tissue specimens from the following biorepositories that will support the Li-CAD P20 studies: 1) a truly remarkable and unique biospecimen bank of samples from Alaska Native (AN) patients with chronic liver disease (“AN biorepository”) from the Alaska Native Tribal Health Consortium (ANTHC); 2) a biospecimen bank of samples from American Indian (AI) patients with chronic liver disease from the Cherokee Nation Health Service (CNHS) (“AI biorepository”) ; and 3) two large non-AI/AN, multiracial/multiethnic biorepositories, that will provide comparison specimens from non-AI/AN patients. The AN biorepository includes >40,000 prospectively and longitudinally collected biospecimens from >3500 patients at the Liver Disease and Hepatitis Program of the ANTHC (Anchorage, AK). This is directed by Dr. Brian McMahon, the PI of the Li-CAD Biospecimen Core and co-PI of the P20 Li-CAD, which will serve to streamline access to these biospecimens for Li-CAD investigators. Biospecimens from these biorepositories will support Projects 1 and 2, as well as future developmental research projects and expanded P50 projects SA2. Expand the biospecimen repository of American Indian patients with liver disease, cirrhosis and HCC based at Cherokee Nation Health Service (CNHS, Tahlequah, OK) and pattern it after our existing, large biorepository of Alaska Native patients at ANTHC. We will augment our biospecimens and patient recruitment from American Indian patients by a new collaboration with Cherokee Nation Health Service (CNHS). We will use our expertise from Alaska Native biorepositories to establish analogous liver disease biorepositories for American Indian patients at CNHS. This will be an invaluable resource, especially as we expand to a P50 SPORE. SA3. Provide core pathology resources in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators